Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 27, 2017updated 22 Nov 2021 10:29am

Deals this week: Alimera Sciences, ThromboGenics, AbbVie

Alimera Sciences plans to raise $100m in a public offering of securities, including common stock, preferred stock, debt securities, warrants and units.

Alimera Sciences plans to raise $100m in a public offering of securities including common stock, preferred stock, debt securities, warrants and units.

The biopharmaceutical company plans to use the funds for general corporate purposes.

ThromboGenics NV plans to raise €10m ($11.82m) through a private placement of shares.

The placement was subscribed to by Novartis.

Biopharmaceutical company AbbVie has signed an agreement with biotechnology company Alector to develop medicines targeting Alzheimer’s disease and other neurodegenerative disorders.

“ThromboGenics NV plans to raise €10m ($11.82m) through a private placement of shares.”

Alector will carry out exploratory research, while AbbVie will have the option to conduct development and commercialisation activities under the agreement.

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

The deal will help the two companies to develop innovative therapies for Alzheimer’s disease. Both companies involved are based in the US.

South Korean pharmaceutical company Choa Pharmaceutical has raised KRW12bn ($10.59m) through a public offering of private convertible bonds.

The bonds are due on 24 April 2022.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU